ArcherDX, Inc. (RCHR)
ArcherDX was planning to go public, but the IPO has been withdrawn.
Stock Price: Pending
IPO price not available yet
| Market Cap | n/a |
| Revenue (ttm) | 55.91M |
| Net Income (ttm) | -54.93M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
There are no news available yet.
About RCHR
ArcherDX is a leading genomics company democratizing precision oncology. We offer a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. This empowers clinicians to control the sample, data, patient care and economics. Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development. We believe these benefits will drive broader adoption of precision oncology throughout the therapeutic continuum, improving patient care. Our produ... [Read more...]
| CEO Jason Myers | Employees 337 |
| Stock Exchange NASDAQ | Ticker Symbol RCHR |